The Emory-Sage-SGC TREAT-AD center is taking an open science approach to promoting the study of under-studied AD genes and proteins by providing packages of information and reagents specific to targets to encourage their research as therapeutic AD targets by the research community. Join Drs. Riham Ayoubi and Alison Axtman to discuss strategies and methods for the selection of adequate cell lines for antibody characterization and the assembly and annotation of the AD Informer Set to enable research of targets identified by the AD consortia. Read about the initiative and sign up for the TREAT-AD webinar.
Join us for an immersion workshop on how to work with AD Knowledge Portal data. This hands-on, virtual workshop will introduce AD Knowledge Portal infrastructure, how to find data and metadata, and how to download and join data in preparation for downstream analyses. If you’d like to participate, please indicate your interest.
The Model Organism Development and Evaluation for Late-onset Alzheimer’s Disease (MODEL-AD) consortium discussed their goals, including the development of new models based on recent human genetics, the alignment of AD pathophysiology in mouse models and human studies, the staging of disease progression, and preclinical testing based on translatable biomarkers.
Dr. Gregory Carter is an Associate Professor at The Jackson Laboratory, Bar Harbor, ME. He combines genetic, genomic, imaging, and other data resources to understand the causes and progression of Alzheimer’s disease.
TREAT-AD is partnering with YCharOS to provide antibody characterization for understudied AD targets. Learn why YCharOS’s CSO Carl Laflamme says “the most cited antibodies are not necessarily the best antibodies.”